Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center

Liver International

Volumn 26, Issue 7, 2006, Pages 796-804

  Fung, Scott K ^a,b   Wong, Florence S H ^a   Wong, David K H ^a   Hussain, Munira T ^b   Lok, Anna S F ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antiviral therapy; Core promoter variant; HBV DNA; HBV genotypes; Hepatitis B virus; Precore variant

Indexed keywords

ALANINE AMINOTRANSFERASE; CORE PROTEIN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; ASIAN; CANADA; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMIGRANT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; PROMOTER REGION; QUANTITATIVE ANALYSIS; TERTIARY HEALTH CARE; VIROLOGY;

ASIAN CONTINENTAL ANCESTRY GROUP; CANADA; GENETIC VARIATION; GENOME, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHYLOGENY; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; VARIATION (GENETICS);

EID: 33746711548     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01297.x     Document Type: Article

References (36)

1. McMahon B, Alberts S R, Wainwright R B, Bulkow L, Lanier A P. Hepatitis B-related sequelae: Prospective study in 1400 hepatitis B surface antigen-positive Alaskan native carriers. Arch Internal Med 1990; 150: 1051-4.
2. McMahon B, Holck P, Bulkow L, Snowball M M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Internal Med 2001; 135: 759-68.
3. Minuk G, Uhanova J. Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 2003; 17: 707-12.
4. Miller J, Finelli L, Bell B P. Incidence of acute hepatitis B -United States, 1990-2002. J Am Med Assoc 2004; 291: 416-47.
5. Lindh M, Andersson A, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus -large scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-93.
6. Magnius L O, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 24-34.
7. Sugauchi F, Orito E, Ichida T, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-92.
8. Sugauchi F, Kumada H, Sakugawa H, et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 2004; 38: 1222-8.
9. Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124: 925-32.
10. Janssen H L, Senturk H, Zeuzem S, et al. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive chronic hepatitis B: A randomized controlled trial in 307 patients (abstract). Hepatology 2003; 38: (Suppl): 246A.
11. Chu C, Hussain M, Lok A. Hepatitis B virus genotype B is associated with earlier spontaneous seroconversion than hepatitis B virus genotype C. Gastroenterology 2003; 122: 1756-62.
12. Chan H L Y, Wong M L, Hui A Y, Hung L C T, Chan F K L, Sung J J Y. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol 2003; 41: 1277-9.
13. Yuen M F, Fung S K, Tanaka Y, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42: 5036-40.
14. Janssen H L, van Zonneveld M, Senturk H, et al. Pegylated interferaon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
15. Carman W F, Jacyna M R, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
16. Naoumov N V, Schneider R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538-43.
17. Chu C M, Chiu C T, Sheen I S, Liaw Y F, Yeh C T. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815-8.
18. Laras A, Koskinas J, Avgidis K, Hadziyannis S J. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241-8.
19. Brunetto M R, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
20. Grandjacques C, Paradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: Correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430-9.
21. Chu C J, Keefe E, Han S H, et al. Hepatitis B virus genotypes in the United States: Results of a nationwide study. Gastroenterology 2003; 125: 444-51.
22. Chu C J, Keeffe E, Han S H, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619-28.
23. Anonymous. Hepatitis B vaccination coverage among Asian and Pacific Islander children -United States, 1998. Morbid Mortal Weekly Rep 2000; 49: 616-9.
24. Chao S, Le P V, Prapong W, Su J, So S. High prevalence of chronic hepatitis B (HBV) infection in Chinese Americans living in California (abstract). Hepatology 2004; 40 (Suppl. 1): 717A.
25. Lok A, McMahon B. Chronic Hepatitis B. Hepatology 2001; 34: 1225-41.
26. Lok A S F, McMahon B J. Chronic Hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.
27. Chan H L Y, Hussain M, Lok A S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976-84.
28. Lok A S F, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
29. Lok A S F, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-34.
30. Statistics Canada. Census 2001, http://www.statcan.ca. 2001.
31. EASL Jury. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003; 39: S3-25.
32. Liaw Y F, Leung N W, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
33. Sherman M, Bain V, Villeneuve J P, et al. Management of viral hepatitis: a Canadian Consensus Conference 2003/2004. Can J Gastroenterol 2004; 18: 715-28.
34. Keeffe E, Dieterich D T, Han S H B, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 86-107.
35. Chan H, Leung N, Hussain M, Wong M, Lok A. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-8.
36. Kim W R, Benson J T, Therneau T M, Torgerson H A, Yawn B P, Melton L J III. Changing epidemiology of hepatitis B in a US community. Hepatology 2004; 39: 811-6.